Clinical Trial Update: Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the effects of GLP-1 receptor agonist therapy on bone metabolism in youths aged 12-21 with obesity; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity in Children

Drugs mentioned

• GLP-1 receptor agonist therapy (glucagon-like peptide-1 receptor agonist)

Snippet

Sponsor: University of Virginia | Conditions: Obesity in Children, Bone Strength | Phase 2 | Status: RECRUITING